<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444533</url>
  </required_header>
  <id_info>
    <org_study_id>14-007071</org_study_id>
    <nct_id>NCT02444533</nct_id>
  </id_info>
  <brief_title>EXPAREL® for Pain After Tonsillectomy</brief_title>
  <official_title>A Phase IV Randomize, Single-Blind, Trial of Liposomal Bupivacaine (EXPAREL®) for Pain Control in Post-Tonsillectomy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether liposomal bupivacaine (long acting
      injectable anesthetic) provides greater post operative pain relief compared to the standard
      post operative pain regiment for tonsillectomy patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be screened in the clinic when being evaluated for indications for
      tonsillectomy. Once the decision to proceed with tonsillectomy is made, the patient will be
      given the information on the study, provided time to review the information and interested
      patients will be consented.

      There will be two stages in the study. The first will be the operative stage, which includes
      the injection during the operation. The second stage is the patient participation stage.
      During this stage, the patient records the amount of oral pain medication usage, oral intake
      after their procedure, in addition to their pain scores. These scores are recorded and
      brought back (or mailed in) to the clinic for collection during the follow up visit,
      approximately 1 month later (patients will keep records for two weeks). The patients will be
      freed from participation in the study after the one month visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score (Pain Scores on a 0/10 Scale)</measure>
    <time_frame>day of surgery, 14 days after surgery</time_frame>
    <description>Subjects recorded pain scores four times a day in a daily pain diary using a Visual Analog Scale with markings from 0 to 10. 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst possible pain&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Medication Usage (Milligrams Used)</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>Subjects recorded pain medication usage in milligrams used of Tylenol, Ibuprofen, and Oxycodone over a 2 week time frame</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Intake (Patient Recorded Oral Intake)</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Subjects recorded oral intake over one week after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Complications ( Allergic Reaction, Swallowing Dysfunction, Hospital Admission Related to the Study Drug)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Patients will be monitored for drug related complications such as allergic reaction, swallowing dysfunction, hospital admission related to the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Post-tonsillectomy Bleeding</measure>
    <time_frame>4 weeks</time_frame>
    <description>The rate of post-tonsillectomy bleeding will be recorded and compared to the arm who did not receive the injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Tonsillectomy</condition>
  <condition>Tonsillitis</condition>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of recurrent tonsillitis or bilateral tonsillar hypertrophy requiring
             bilateral tonsillectomy

          -  Willing and able to understand and provide written informed consent

        Exclusion Criteria:

          -  Known pregnancy

          -  Women who are currently nursing a child

          -  History of coagulopathy; such as hemophilia or Von Willebrand disease, or any
             congenital or acquired bleeding disorder

          -  Use of anticoagulation medication during the study, i.e. aspirin, Coumadin, Plavix, or
             medications similar in class to these medications will exclude the patient from
             participation

          -  Inability to provide informed consent (patients under guardianship)

          -  Known hypersensitivity to local anesthetics

          -  History of cardiac disease; such as current impaired cardiovascular function, past
             history of myocardial infarction, congenital heart disease, current cardiac symptoms,
             i.e. angina, shortness of breath, or chest pain as determined by history or review of
             the medical record.

          -  History of complex pulmonary disease; such as uncontrolled asthma, chronic obstructive
             pulmonary disease (COPD), or interstitial lung disease as determined by history or
             review of the medical record.

          -  Impaired renal function as documented in the medical record in the last 3 months with
             a serum creatinine greater than 1.2 mg/dL or glomerular filtration rate &lt; 60
             mL/min/body surface area (BSA) as determined by history or review of the medical
             record.

          -  History of or current hepatic disease as documented by liver function test abnormality
             in the last 3 months as determined by history or review of the medical record.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel L Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <results_first_submitted>April 20, 2017</results_first_submitted>
  <results_first_submitted_qc>June 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2017</results_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Daniel L. Price, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Liposomal Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at the Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivacaine</title>
          <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
Liposomal Bupivacaine: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
        </group>
        <group group_id="P2">
          <title>No Treatment</title>
          <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not able to complete forms</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Only gave post-procedure complications</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographics include only subjects who were reported as having at least partial outcome data.</population>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivacaine</title>
          <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
Liposomal Bupivacaine: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
        </group>
        <group group_id="B2">
          <title>No Treatment</title>
          <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score (Pain Scores on a 0/10 Scale)</title>
        <description>Subjects recorded pain scores four times a day in a daily pain diary using a Visual Analog Scale with markings from 0 to 10. 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst possible pain&quot;</description>
        <time_frame>day of surgery, 14 days after surgery</time_frame>
        <population>Results include only subjects who were reported as having at least partial outcome data.</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
Liposomal Bupivacaine: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score (Pain Scores on a 0/10 Scale)</title>
          <description>Subjects recorded pain scores four times a day in a daily pain diary using a Visual Analog Scale with markings from 0 to 10. 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst possible pain&quot;</description>
          <population>Results include only subjects who were reported as having at least partial outcome data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day of surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" spread="2.03"/>
                    <measurement group_id="O2" value="4.9" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 days after surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.44"/>
                    <measurement group_id="O2" value="1.42" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups for pain on day of surgery. Statistical significance was defined as a p-value less than 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups for pain at 14 days after surgery. Statistical significance was defined as a p-value less than 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.445</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Medication Usage (Milligrams Used)</title>
        <description>Subjects recorded pain medication usage in milligrams used of Tylenol, Ibuprofen, and Oxycodone over a 2 week time frame</description>
        <time_frame>2 weeks after surgery</time_frame>
        <population>One subject on the no treatment arm was excluded for lack of follow up data, therefore 18 (from participant flow) -1 = 17.</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
Liposomal Bupivacaine: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Medication Usage (Milligrams Used)</title>
          <description>Subjects recorded pain medication usage in milligrams used of Tylenol, Ibuprofen, and Oxycodone over a 2 week time frame</description>
          <population>One subject on the no treatment arm was excluded for lack of follow up data, therefore 18 (from participant flow) -1 = 17.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ibuprofen (Motrin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14013" spread="18109"/>
                    <measurement group_id="O2" value="9753" spread="11509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen (Tylenol)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30615" spread="13196"/>
                    <measurement group_id="O2" value="31287" spread="13185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone (OxyContin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265" spread="246"/>
                    <measurement group_id="O2" value="244" spread="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups for ibuprofen usage. Statistical significance was defined as a p-value less than 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.650</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups for acetaminophen usage. Statistical significance was defined as a p-value less than 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.970</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups for oxycodone usage. Statistical significance was defined as a p-value less than 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.835</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oral Intake (Patient Recorded Oral Intake)</title>
        <description>Subjects recorded oral intake over one week after surgery</description>
        <time_frame>1 week after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
Liposomal Bupivacaine: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Intake (Patient Recorded Oral Intake)</title>
          <description>Subjects recorded oral intake over one week after surgery</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13715" spread="7551"/>
                    <measurement group_id="O2" value="12492" spread="4271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups at 7 days. Statistical significance was defined as a p-value less than 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Complications ( Allergic Reaction, Swallowing Dysfunction, Hospital Admission Related to the Study Drug)</title>
        <description>Patients will be monitored for drug related complications such as allergic reaction, swallowing dysfunction, hospital admission related to the study drug.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
Liposomal Bupivacaine: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Complications ( Allergic Reaction, Swallowing Dysfunction, Hospital Admission Related to the Study Drug)</title>
          <description>Patients will be monitored for drug related complications such as allergic reaction, swallowing dysfunction, hospital admission related to the study drug.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Allergic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swallowing dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital admission related to the study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Post-tonsillectomy Bleeding</title>
        <description>The rate of post-tonsillectomy bleeding will be recorded and compared to the arm who did not receive the injection.</description>
        <time_frame>4 weeks</time_frame>
        <population>In the Liposomal Bupivacaine arm, 15 subjects had data on the primary endpoints, and an additional 2 provided information regarding post-procedure complications, but didn't provide data on other outcomes, therefore the analysis population for the Liposomal Bupivacaine is 17.</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
Liposomal Bupivacaine: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Post-tonsillectomy Bleeding</title>
          <description>The rate of post-tonsillectomy bleeding will be recorded and compared to the arm who did not receive the injection.</description>
          <population>In the Liposomal Bupivacaine arm, 15 subjects had data on the primary endpoints, and an additional 2 provided information regarding post-procedure complications, but didn't provide data on other outcomes, therefore the analysis population for the Liposomal Bupivacaine is 17.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any form of bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required a trip back to the operating room</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 weeks post surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivacaine</title>
          <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy.
Liposomal Bupivacaine: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
        </group>
        <group group_id="E2">
          <title>No Treatment</title>
          <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Price</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-293-4395</phone>
      <email>Price.Daniel@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

